ImaRx Therapeutics, which is developing novel therapies for vascular disorders associated with blood clots, priced 3 million shares at the revised price of $5 per share. The firm originally filed to offer 3 million shares at a price range of $6.50 to $7.50 per share. Maxim Group is the lead manager on the deal. The stock is expected to begin trading on the NASDAQ Thursday under the ticker "IMRX."
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
